Patents by Inventor Qiumei Yang

Qiumei Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230281265
    Abstract: The present disclosure provides a method for estimating a body size and weight of a pig based on deep learning, and relates to the technical field of deep learning. The present disclosure predicts the weight of the pig by using a convolutional neural network. Relevant features are learned by the convolutional neural network, and feature engineering extraction is not needed to be established, so that extracted features are more comprehensive, and the convolutional neural network is superior to a linear model in processing of noisy data and nonlinear problems of data. Images of the pig are shot by an ordinary two-dimensional (2d) color camera.
    Type: Application
    Filed: December 30, 2021
    Publication date: September 7, 2023
    Applicant: SOUTH CHINA AGRICULTURAL UNIVERSITY
    Inventors: Deqin XIAO, Junbin LIU, Youfu LIU, Qiumei YANG, Yigui HUANG, Wentao YANG, Shengqiu ZHAO, Zhiyi BIAN
  • Publication number: 20230052970
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
    Type: Application
    Filed: October 3, 2022
    Publication date: February 16, 2023
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, David Glass, Thomas Huber, Julia Jascur, Carl H. June, Jihyun Lee, Joan Mannick, Michael C. Milone, Leon Murphy, Avery D. Posey, Huijuan Song, Yongqiang Wang, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Patent number: 11459390
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: October 4, 2022
    Assignees: Novartis AG, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, David Glass, Thomas Huber, Julia Jascur, Carl H. June, Jihyun Lee, Joan Mannick, Michael C. Milone, Leon Murphy, Avery D. Posey, Huijuan Song, Yongqiang Wang, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Publication number: 20210284724
    Abstract: Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.
    Type: Application
    Filed: May 20, 2021
    Publication date: September 16, 2021
    Inventors: Haijuan Gu, Qiumei Yang
  • Publication number: 20210198368
    Abstract: The present invention is directed to multispecific/multivalent molecules comprising an anti-CLL-1 binding domain.
    Type: Application
    Filed: January 20, 2017
    Publication date: July 1, 2021
    Inventors: Michael DALEY, Hilmar EBERSBACH, Julia JASCUR, Qilong WU, Qiumei YANG, Jiquan ZHANG
  • Patent number: 11034771
    Abstract: Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific antibodies are effective in treating cancer.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: June 15, 2021
    Assignee: I-Mab Biopharma US Limited
    Inventors: Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang, Qiumei Yang
  • Patent number: 11028164
    Abstract: Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL 13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: June 8, 2021
    Assignee: I-Mab Biopharma US Limited
    Inventors: Haijuan Gu, Qiumei Yang
  • Publication number: 20200399360
    Abstract: Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL 13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.
    Type: Application
    Filed: September 18, 2019
    Publication date: December 24, 2020
    Inventors: Haijuan Gu, Qiumei Yang
  • Publication number: 20200347146
    Abstract: Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific C antibodies are effective in treating cancer.
    Type: Application
    Filed: July 25, 2019
    Publication date: November 5, 2020
    Inventors: Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang, Qiumei Yang
  • Publication number: 20200215171
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Application
    Filed: December 27, 2019
    Publication date: July 9, 2020
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Jonathan Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Patent number: 10568947
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: February 25, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Publication number: 20180118834
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
    Type: Application
    Filed: January 15, 2016
    Publication date: May 3, 2018
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, David Glass, Thomas Huber, Julia Jascur, Carl H. June, Jihyun Lee, Joan Mannick, Michael C. Milone, Leon Murphy, Avery D. Posey, Huijuan Song, Yongqiang Wang, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Publication number: 20160051651
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Application
    Filed: July 21, 2015
    Publication date: February 25, 2016
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Publication number: 20140157459
    Abstract: Involved is pesticidal gene and use thereof, the nucleotide sequence of the pesticidal gene comprises: (a) a nucleotide sequence as shown in SEQ ID NO: 3; or (b) a nucleotide sequence as shown in SEQ ID NO: 4; or (c) an isocoding sequence of (a) or (b) which is not the nucleotide sequence as shown in SEQ ID: 22 or SEQ ID NO: 26; or (d) a nucleotide sequence which hybridizes with the nucleotide sequence as shown in (a), (b) or (c) under stringency conditions and encodes a protein having pesticidal activity. The pesticidal gene of present application is particularly suitable for expression in monocotyledonae and notably increases the expression level, stability and virulence of pesticidal protein Vip3A. At the same time, in present application, Sesamia inferens is controlled by the Vip3A protein having pesticidal activity against Sesamia inferens, which is produced in the plants.
    Type: Application
    Filed: December 5, 2013
    Publication date: June 5, 2014
    Applicants: Beijing Dabeinong Technology Group Co., Ltd., Beijing Green Agrosino Plant Protection Technology Co., Ltd., Beijing Dabeinong Technology Group Co., Ltd. , Biotech Center
    Inventors: Chao HAN, Jie Pang, Derong Ding, Yuejing Kang, Lijun Wang, Yanlong Liang, Yanhua Liu, Yingjia Qian, Qiumei Yang, Kangle Tian, Xiaona Zhao